Nothing Special   »   [go: up one dir, main page]

EA201491541A1 - АНТИТЕЛА ПРОТИВ ИНТЕГРИНОВ αvβ6 И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННЫХ НОВООБРАЗОВАНИЙ - Google Patents

АНТИТЕЛА ПРОТИВ ИНТЕГРИНОВ αvβ6 И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННЫХ НОВООБРАЗОВАНИЙ

Info

Publication number
EA201491541A1
EA201491541A1 EA201491541A EA201491541A EA201491541A1 EA 201491541 A1 EA201491541 A1 EA 201491541A1 EA 201491541 A EA201491541 A EA 201491541A EA 201491541 A EA201491541 A EA 201491541A EA 201491541 A1 EA201491541 A1 EA 201491541A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
malignant
noroves
integrines
application
Prior art date
Application number
EA201491541A
Other languages
English (en)
Other versions
EA031069B1 (ru
Inventor
Морин РАЙАН
Джанго Сассман
Original Assignee
Сиэтл Дженетикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сиэтл Дженетикс, Инк. filed Critical Сиэтл Дженетикс, Инк.
Publication of EA201491541A1 publication Critical patent/EA201491541A1/ru
Publication of EA031069B1 publication Critical patent/EA031069B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Изобретение относится к антителам, которые специфично связываются с интегрином αvβ6. Антитела могут быть полезными для лечения и диагностики различных видов злокачественных заболеваний, а также для детекции αvβ6.
EA201491541A 2012-02-17 2013-02-14 АНТИТЕЛА ПРОТИВ ИНТЕГРИНОВ αVβ6 И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННЫХ НОВООБРАЗОВАНИЙ EA031069B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261600499P 2012-02-17 2012-02-17
US201261602511P 2012-02-23 2012-02-23
PCT/US2013/026087 WO2013123152A2 (en) 2012-02-17 2013-02-14 ANTIBODIES TO INTEGRIN αVβ6 AND USE OF SAME TO TREAT CANCER

Publications (2)

Publication Number Publication Date
EA201491541A1 true EA201491541A1 (ru) 2016-05-31
EA031069B1 EA031069B1 (ru) 2018-11-30

Family

ID=48984888

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201491541A EA031069B1 (ru) 2012-02-17 2013-02-14 АНТИТЕЛА ПРОТИВ ИНТЕГРИНОВ αVβ6 И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННЫХ НОВООБРАЗОВАНИЙ

Country Status (14)

Country Link
US (5) US9493566B2 (ru)
EP (1) EP2814509B1 (ru)
JP (1) JP6273214B2 (ru)
KR (1) KR102084806B1 (ru)
CN (2) CN105017420B (ru)
AU (1) AU2013221585B2 (ru)
BR (1) BR112014019861A2 (ru)
CA (1) CA2862319C (ru)
EA (1) EA031069B1 (ru)
HK (1) HK1211035A1 (ru)
IL (1) IL233742B (ru)
MX (1) MX360141B (ru)
SG (1) SG11201404354UA (ru)
WO (1) WO2013123152A2 (ru)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2616728T3 (es) 2008-05-23 2017-06-14 Siwa Corporation Procedimientos y composiciones para facilitar la regeneración
CA2925057A1 (en) * 2013-10-01 2015-04-09 Simon T. BARRY Methods of treating and diagnosing alpha-v-beta-6 overexpressing cancer
KR20240034882A (ko) 2013-10-15 2024-03-14 씨젠 인크. 개선된 리간드-약물 컨쥬게이트 약물동력학을 위한 peg화된 약물-링커
IL290116B2 (en) 2014-02-17 2024-06-01 Seagen Inc Hydrophilic antibody-drug conjugates
US20170233452A1 (en) * 2014-04-23 2017-08-17 Immusoft Corporation Chimeric antigen receptors specific to avb6 integrin and methods of use thereof to treat cancer
US9993535B2 (en) 2014-12-18 2018-06-12 Siwa Corporation Method and composition for treating sarcopenia
US10358502B2 (en) 2014-12-18 2019-07-23 Siwa Corporation Product and method for treating sarcopenia
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
EP3383420B1 (en) 2015-12-04 2022-03-23 Seagen Inc. Conjugates of quaternized tubulysin compounds
US11833202B2 (en) 2016-02-19 2023-12-05 Siwa Corporation Method and composition for treating cancer, killing metastatic cancer cells and preventing cancer metastasis using antibody to advanced glycation end products (AGE)
KR102626498B1 (ko) 2016-03-25 2024-01-19 씨젠 인크. 페길화된 약물-링커 및 그의 중간체의 제조를 위한 공정
US11958900B2 (en) 2016-04-15 2024-04-16 Siwa Corporation Anti-age antibodies for treating neurodegenerative disorders
JP7257951B2 (ja) 2016-08-09 2023-04-14 シージェン インコーポレイテッド 改善された生理化学的特性を有する自己安定性リンカーを用いる薬物コンジュゲート
IL291810A (en) 2016-10-18 2022-06-01 Seagen Inc Targeted administration of nicotinamide adenine dinucleotide reductase pathway inhibitors
EP3981780A1 (en) * 2016-11-01 2022-04-13 Arrowhead Pharmaceuticals, Inc. Alpha-v beta-6 integrin ligands and uses thereof
WO2018107116A1 (en) * 2016-12-09 2018-06-14 Abbvie Stemcentrx Llc Methods of reducing toxicity of antibody drug conjugates, and compositions produced thereby
JP7244987B2 (ja) 2016-12-14 2023-03-23 シージェン インコーポレイテッド 多剤抗体薬物コンジュゲート
CA3056134A1 (en) 2017-03-24 2018-09-27 Seattle Genetics, Inc. Process for the preparation of glucuronide drug-linkers and intermediates thereof
BR112019021471A2 (pt) * 2017-04-13 2020-05-12 Siwa Corporation Anticorpo monoclonal humanizado de produto final da glicação avançada
BR112019022445A2 (pt) 2017-04-27 2020-05-12 Seattle Genetics, Inc. Composição de conjugado ligante-fármaco, formulação, método para inibir a multiplicação de uma célula tumoral ou célula cancerosa ou causar apoptose em uma célula tumoral ou cancerosa, e, composto de conector de fármaco
JP7445594B2 (ja) 2017-11-01 2024-03-07 アローヘッド ファーマシューティカルズ インコーポレイテッド インテグリンリガンドおよびその使用
US11518801B1 (en) 2017-12-22 2022-12-06 Siwa Corporation Methods and compositions for treating diabetes and diabetic complications
MX2020008267A (es) 2018-02-20 2020-09-21 Seattle Genetics Inc Compuestos de auristatina f hidrofoba y conjugados de los mismos.
US20240199735A1 (en) * 2019-07-22 2024-06-20 The Methodist Hospital Microfibrillar-Associated Protein 5 (MFAP5)-Targeting Monoclonal Antibodies and Methods for Use in Treating Cancer
MX2022006132A (es) * 2019-12-05 2022-06-17 Seagen Inc Anticuerpos anti alfa-v beta-6 (avb6) y conjugados de anticuerpo-farmaco.
JP2023509760A (ja) 2020-01-08 2023-03-09 シンシス セラピューティクス，インコーポレイテッド Ａｌｋ５阻害剤複合体およびその使用
BR112022020332A2 (pt) 2020-04-10 2022-12-13 Seagen Inc Composto conjugado anticorpo-droga, composição, método de tratamento de câncer e de um distúrbio autoimune
US12036286B2 (en) 2021-03-18 2024-07-16 Seagen Inc. Selective drug release from internalized conjugates of biologically active compounds
TW202304514A (zh) 2021-04-20 2023-02-01 美商思進公司 抗體依賴性細胞毒性之調節
KR20240015670A (ko) 2021-05-28 2024-02-05 씨젠 인크. 안트라사이클린 항체 접합체
US20230381321A1 (en) 2022-03-17 2023-11-30 Seagan Inc., Camptothecin conjugates
WO2024129756A1 (en) 2022-12-13 2024-06-20 Seagen Inc. Site-specific engineered cysteine antibody drug conjugates
WO2024137442A1 (en) 2022-12-21 2024-06-27 Gilead Sciences, Inc. Combination therapy for treating cancer

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962643A (en) 1991-07-11 1999-10-05 The Regents Of The University Of California Integrin β subunit and uses thereof
PT1504764E (pt) 1997-08-08 2009-01-14 Univ California Tratamento da fibrose hepática com anticorpos contra integrina alfa-v-beta 6
WO2002088306A2 (en) 2001-04-30 2002-11-07 Eli Lilly And Company Humanized antibodies
EP2287198A3 (en) * 2002-03-13 2011-05-25 Biogen Idec MA Inc. Anti-alpha V beta 6 antibodies
CN100509851C (zh) * 2002-03-13 2009-07-08 拜奥根Idec马萨诸塞公司 抗αvβ6抗体
EP1492870A4 (en) 2002-04-12 2005-08-03 Raven Biotechnologies Inc ANTIBODIES BINDING TO INTEGRIN-ALPHA-V-BETA-6 AND METHOD OF USE THEREOF
US7241598B2 (en) * 2004-06-29 2007-07-10 The Chinese University Of Hong Kong Frame-shifting PCR for germline immunoglobulin genes retrieval and antibody engineering
AU2005294373B2 (en) * 2004-10-05 2011-12-08 Janssen Alzheimer Immunotherapy Methods and compositions for improving recombinant protein production
HUE025449T2 (en) * 2004-12-09 2016-04-28 Janssen Biotech Inc Immunoconjugates against Integrin, a method for their preparation and use
WO2006099141A2 (en) * 2005-03-10 2006-09-21 Morphotek, Inc. Anti-mesothelin antibodies
CN102875681A (zh) 2005-07-08 2013-01-16 拜奥根Idec马萨诸塞公司 抗-αvβ6抗体及其用途
EP1928911A2 (en) 2005-08-31 2008-06-11 Novo Nordisk Health Care AG Human fvii monoclonal antibodies binding the gla domain and use thereof
CL2007002225A1 (es) * 2006-08-03 2008-04-18 Astrazeneca Ab Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
CN101553505B (zh) 2006-08-03 2013-07-17 阿斯利康(瑞典)有限公司 针对αVβ6的抗体及其应用
EP2087008A1 (en) 2006-10-19 2009-08-12 The Regents of the University of California TREATMENT AND PREVENTION OF CHRONIC ASTHMA USING ANTAGONISTS OF INTEGRIN alphaVbeta6
SG187457A1 (en) * 2008-01-11 2013-02-28 Univ Tokyo Anti-cldn6 antibody
AU2009206724A1 (en) * 2008-01-22 2009-07-30 Biogen Idec Ma Inc. RON antibodies and uses thereof
JP5467997B2 (ja) 2008-03-27 2014-04-09 テルモ株式会社 生体吸収性材料およびそれを用いた生体内留置物
WO2009135953A2 (en) 2008-05-09 2009-11-12 Ablynx Nv Amino acid sequences directed against integrins and uses thereof
JP2010210772A (ja) * 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd 液晶表示装置の製造方法
WO2011046309A2 (en) * 2009-10-12 2011-04-21 Korea Research Institute Of Bioscience And Biotechnology A diagnostic marker for hepatocellular carcinoma comprising anti-fasn autoantibodies and a diagnostic composition for hepatocellular carcinoma comprising antigens thereof
KR101138460B1 (ko) * 2009-10-12 2012-04-26 한국생명공학연구원 항-ｆａｓｎ 자가면역 항체를 포함하는 간암 진단 마커 및 이의 항원을 포함하는 간암 진단용 조성물
EA029419B1 (ru) 2010-11-19 2018-03-30 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Нейтрализующие антитела против ccl20
US20150086570A1 (en) 2012-03-29 2015-03-26 Biogen Idec Ma Inc. Biomarkers for use in integrin therapy applications

Also Published As

Publication number Publication date
HK1211035A1 (en) 2016-05-13
SG11201404354UA (en) 2014-10-30
CN104220094A (zh) 2014-12-17
CA2862319C (en) 2021-11-30
EP2814509B1 (en) 2018-05-16
US20210340260A1 (en) 2021-11-04
MX360141B (es) 2018-10-24
CN105017420A (zh) 2015-11-04
US20160376368A1 (en) 2016-12-29
BR112014019861A2 (pt) 2017-07-04
AU2013221585A1 (en) 2014-08-14
WO2013123152A3 (en) 2014-11-13
EA031069B1 (ru) 2018-11-30
US20200031938A1 (en) 2020-01-30
JP2015509938A (ja) 2015-04-02
US20160009806A1 (en) 2016-01-14
JP6273214B2 (ja) 2018-01-31
AU2013221585B2 (en) 2017-03-30
US9493566B2 (en) 2016-11-15
CN105017420B (zh) 2019-05-28
EP2814509A4 (en) 2015-12-09
MX2014009751A (es) 2015-02-24
IL233742B (en) 2019-08-29
IL233742A0 (en) 2014-09-30
EP2814509A2 (en) 2014-12-24
KR102084806B1 (ko) 2020-03-04
CA2862319A1 (en) 2013-08-22
US20230242648A1 (en) 2023-08-03
KR20140127875A (ko) 2014-11-04
WO2013123152A2 (en) 2013-08-22

Similar Documents

Publication Publication Date Title
EA201491541A1 (ru) АНТИТЕЛА ПРОТИВ ИНТЕГРИНОВ αvβ6 И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННЫХ НОВООБРАЗОВАНИЙ
EA201492137A1 (ru) Антитела к cd33 и их применение в лечении рака
EA201491811A1 (ru) АНТИ-LgR5 АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ
EA201491947A1 (ru) Антитела и иммуноконъюгаты к ly6e и способы применения
EA201390929A1 (ru) Антитела к pcsk9 и способы их применения
EA201491357A1 (ru) Анти-lrp5 антитела и способы их применения
EA201590993A1 (ru) Гетеродимерные иммуноглобулины
EA201490778A1 (ru) АНТИТЕЛА ПРОТИВ HtrA1 И СПОСОБЫ ПРИМЕНЕНИЯ
MA34091B1 (fr) Anticorps anti-cd40
EA201790413A1 (ru) Антитела против tigit
EA202193044A2 (ru) Способы лечения таупатии
EA201391507A1 (ru) АНТИТЕЛА ПРОТИВ c-Kit И ИХ ПРИМЕНЕНИЕ
EA201491224A1 (ru) Анти-псф-тау-антитела и их применение
EA201201016A1 (ru) Антидоты антикоагулянтов
EA201391540A1 (ru) Агонисты fgfr1 и способы их применения
EA201691214A1 (ru) Антитела к cd33 и иммуноконъюгаты
EA201400875A1 (ru) Антитела к cd47 и способы их применения
EA201891833A1 (ru) Комбинация для лечения амиотрофического бокового склероза или родственных болезней
EA201591750A1 (ru) Антитела против b7-h4 и иммуноконъюгаты
EA201400579A1 (ru) Антитела к il-36r
EA201892509A1 (ru) Антитела к гемагглютинину и способы применения
EA201500314A1 (ru) Лекарственные формы энзалутамида
EA201390274A1 (ru) Борсодержащие малые молекулы
EA201490717A1 (ru) АНТИТЕЛА К ErbB3 И ИХ ПРИМЕНЕНИЕ
EA201390472A1 (ru) Новые молекулы, связывающиеся с egfr, и их иммуноконъюгаты

Legal Events

Date Code Title Description
TC4A Change in name of a patent proprietor in a eurasian patent